Data Insights

CD70 CAR-T by UTC Therapeutics for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase I for Transitional Cell Cancer (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

CD70 CAR-T by UTC Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase I for Kidney Cancer (Renal Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Kidney Cancer (Renal Cell Cancer)

Data Insights

CD70 CAR-T by UTC Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Marginal Zone B-cell Lymphoma

Data Insights

CD70 CAR-T by UTC Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

CD70 CAR-T by UTC Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in B-Cell Non-Hodgkin Lymphoma

Data Insights

CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

CD70 CAR-T by UTC Therapeutics for Follicular Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Follicular Lymphoma

Data Insights

CD70 CAR-T by UTC Therapeutics for Burkitt Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Burkitt Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Burkitt Lymphoma

Data Insights

CD70 CAR-T by UTC Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Mantle Cell Lymphoma

Data Insights

CD70 CAR-T by UTC Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T in Diffuse Large B-Cell Lymphoma